CoChat
Sign Up
Cited by 60

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The Lipoprotein Lipase Inhibitor ANGPTL3 Is Negatively Regulated by Thyroid Hormone

Fugier, Charlotte, Tousaint, Jean-Jacques, Prieur, Xavier, Plateroti, Michelina, Samarut, Jacques, Delerive, Philippe·2006·Journal of Biological Chemistry
DOI 10.1074/jbc.m512554200
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m512554200

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY · From the PDF
Image 2
CC-BY · From the PDF
Image 3
CC-BY · From the PDF
Image 4
CC-BY · From the PDF
Image 5
CC-BY · From the PDF
FIGURE 3 TR 𝛃 activation leads to ANGPTL3 promoter repression in HepG2 cells. A , HepG2 cells were transfected with the human ANGPTL3 promoter ( -929 to + 109 ANGPTL3 -Luc; 40 ng) in the presence of TR 𝛃 or empty vector (pSG5; 10 ng). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS and various TR agonists (100 nM) or vehicle (Me2SO( DMSO ), 0.1%) for an additional 24 h. B , HepG2 cells were transfected with the human ANGPTL3 promoter ( -929 to + 109 ANGPTL3 -Luc; 40 ng) in the presence of TR 𝛃 or empty vector (pSG5; 10 ng). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS and increasing concentrations of T3 or vehicle (0.1% ethanol) for an additional 24 h. Results are plotted as repression levels.
FIGURE 3 TR 𝛃 activation leads to ANGPTL3 promoter repression in HepG2 cells. A , HepG2 cells were transfected with the human ANGPTL3 promoter ( -929 to + 109 ANGPTL3 -Luc; 40 ng) in the presence of TR 𝛃 or empty vector (pSG5; 10 ng). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS and various TR agonists (100 nM) or vehicle (Me2SO( DMSO ), 0.1%) for an additional 24 h. B , HepG2 cells were transfected with the human ANGPTL3 promoter ( -929 to + 109 ANGPTL3 -Luc; 40 ng) in the presence of TR 𝛃 or empty vector (pSG5; 10 ng). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS and increasing concentrations of T3 or vehicle (0.1% ethanol) for an additional 24 h. Results are plotted as repression levels.CC-BY · From the PDF
FIGURE 5 The H11546 171 to ÷ 66 region of the ANGPTL3 promoter confers TR 𝛃 responsiveness. HepG2cellsweretransfectedwithvarious5 ′ -deletions of the human ANGPTL3 promoter (40 ng) and TR 𝛃 or empty vector (pSG5; 10 ng). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS in the presence of T3 (100 nM) or vehicle (ethanol 0.1%) for an additional 24 h. Results are plotted as repression levels. *, p < 0.05.
FIGURE 5 The H11546 171 to ÷ 66 region of the ANGPTL3 promoter confers TR 𝛃 responsiveness. HepG2cellsweretransfectedwithvarious5 ′ -deletions of the human ANGPTL3 promoter (40 ng) and TR 𝛃 or empty vector (pSG5; 10 ng). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS in the presence of T3 (100 nM) or vehicle (ethanol 0.1%) for an additional 24 h. Results are plotted as repression levels. *, p < 0.05.CC-BY · From the PDF
FIGURE 4 TR 𝛃 represses ANGPTL3 promoter activity in a DNA binding-independent manner. HepG2cellsweretransfectedwiththehuman ANGPTL3 promoter ( -929 to + 109 ANGPTL3 -Luc; 40 ng) in the presence of increasing concentrations of pGS5-TR 𝛃 ( A ) or GAL4-TR 𝛃 ( B ) or empty vector (pSG5 and GAL4, respectively). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS in the presence of T3 (100 nM) or vehicle (ethanol 0.1%) for an additional 24 h. Results are plotted as repression levels.
FIGURE 4 TR 𝛃 represses ANGPTL3 promoter activity in a DNA binding-independent manner. HepG2cellsweretransfectedwiththehuman ANGPTL3 promoter ( -929 to + 109 ANGPTL3 -Luc; 40 ng) in the presence of increasing concentrations of pGS5-TR 𝛃 ( A ) or GAL4-TR 𝛃 ( B ) or empty vector (pSG5 and GAL4, respectively). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS in the presence of T3 (100 nM) or vehicle (ethanol 0.1%) for an additional 24 h. Results are plotted as repression levels.CC-BY · From the PDF
Image 9
CC-BY · From the PDF
FIGURE 6 TheHNF1sitewithin the ANGPTL3 promoter is required for TR 𝛃 -dependent repression. HepG2 cells were transfected with wild type or LXR response elementmutated or HNF1 response element-mutated promoter construct (40 ng) and TR 𝛃 or emptyvector(pSG5;10ng).24hlater,cellswererefedwithfreshmediumsupplemented with 1% charcoal/dextran-treated FBS in the presence of T3 (100 nM) or vehicle (ethanol 0.1%) for an additional 24 h. Results are plotted as repression levels. *, p < 0.05.
FIGURE 6 TheHNF1sitewithin the ANGPTL3 promoter is required for TR 𝛃 -dependent repression. HepG2 cells were transfected with wild type or LXR response elementmutated or HNF1 response element-mutated promoter construct (40 ng) and TR 𝛃 or emptyvector(pSG5;10ng).24hlater,cellswererefedwithfreshmediumsupplemented with 1% charcoal/dextran-treated FBS in the presence of T3 (100 nM) or vehicle (ethanol 0.1%) for an additional 24 h. Results are plotted as repression levels. *, p < 0.05.CC-BY · From the PDF
Image 11
CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 50

  1. Mangelsdorf, 1995, Cell, 83, 835, 10.1016/0092-8674(95)90199-X · DOI · Paper page
  2. Lazar, 1993, Endocr. Rev., 14, 184
  3. Moore, 2005, Mol. Cell Proteomics, 4, 475, 10.1074/mcp.R500001-MCP200 · DOI
  4. Wu, 2000, Trends Endocrinol. Metab., 11, 207, 10.1016/S1043-2760(00)00263-0 · DOI
  5. Flamant, 2003, Trends Endocrinol. Metab., 14, 85, 10.1016/S1043-2760(02)00043-7 · DOI · Paper page
  6. Duntas, 2002, Thyroid, 12, 287, 10.1089/10507250252949405 · DOI · Paper page
  7. Hansson, 1983, Horm. Metab. Res., 15, 449, 10.1055/s-2007-1018751 · DOI
  8. Aviram, 1982, Clin. Biochem., 15, 62, 10.1016/S0009-9120(82)90529-X · DOI
  9. Engelken, 1981, Atherosclerosis, 38, 177, 10.1016/0021-9150(81)90114-3 · DOI
  10. Gullberg, 2002, Mol. Endocrinol., 16, 1767, 10.1210/me.2002-0009 · DOI
  11. Gullberg, 2000, Mol. Endocrinol., 14, 1739
  12. Johansson, 2005, Proc. Natl. Acad. Sci. U. S. A., 102, 10297, 10.1073/pnas.0504379102 · DOI
  13. Ness, 1998, Biochem. Pharmacol., 56, 121, 10.1016/S0006-2952(98)00119-1 · DOI
  14. Taylor, 1997, Mol. Pharmacol., 52, 542, 10.1124/mol.52.3.542 · DOI
  15. Trost, 2000, Endocrinology, 141, 3057, 10.1210/endo.141.9.7681 · DOI
  16. Abrams, 1981, J. Lipid Res., 22, 307, 10.1016/S0022-2275(20)35374-8 · DOI
  17. Ito, 2003, Clin. Endocrinol. (Oxf), 58, 621, 10.1046/j.1365-2265.2003.01762.x · DOI
  18. Nikkila, 1972, J. Clin. Invest., 51, 2103, 10.1172/JCI107017 · DOI
  19. Oike, 2005, Trends Mol. Med.
  20. Koishi, 2002, Nat. Genet., 30, 151, 10.1038/ng814 · DOI · Paper page
  21. Shimizugawa, 2002, J. Biol. Chem., 277, 33742, 10.1074/jbc.M203215200 · DOI · Paper page
  22. Shimamura, 2003, Biochem. Biophys. Res. Commun., 301, 604, 10.1016/S0006-291X(02)03058-9 · DOI
  23. Korstanje, 2004, Atherosclerosis, 177, 443, 10.1016/j.atherosclerosis.2004.08.006 · DOI
  24. Yoshida, 2002, J. Lipid Res., 43, 1770, 10.1194/jlr.C200010-JLR200 · DOI · Paper page
  25. Kersten, 2000, J. Biol. Chem., 275, 28488, 10.1074/jbc.M004029200 · DOI · Paper page
  26. Yu, 2005, Proc. Natl. Acad. Sci. U. S. A., 102, 1767, 10.1073/pnas.0409564102 · DOI · Paper page
  27. Chiellini, 1998, Chem. Biol., 5, 299, 10.1016/S1074-5521(98)90168-5 · DOI
  28. Gauthier, 2001, Mol. Cell. Biol., 21, 4748, 10.1128/MCB.21.14.4748-4760.2001 · DOI
  29. Gauthier, 1999, EMBO J., 18, 623, 10.1093/emboj/18.3.623 · DOI
  30. Delerive, 2004, Mol. Endocrinol., 18, 2378, 10.1210/me.2004-0132 · DOI
  31. Dignam, 1983, Methods Enzymol., 101, 582, 10.1016/0076-6879(83)01039-3 · DOI
  32. Dignam, 1983, Healthc. Financ. Manage., 37, 38
  33. Flores-Morales, 2002, Mol. Endocrinol., 16, 1257
  34. Shin, 2003, J. Biol. Chem., 278, 34114, 10.1074/jbc.M305417200 · DOI
  35. Xiong, 1998, Proc. Natl. Acad. Sci. U. S. A., 95, 12260, 10.1073/pnas.95.21.12260 · DOI
  36. Staton, 1998, Endocrinology, 139, 1093, 10.1210/endo.139.3.5799 · DOI
  37. Kaplan, 2003, J. Lipid Res., 44, 136, 10.1194/jlr.M200367-JLR200 · DOI · Paper page
  38. Weiss, 1998, Endocrinology, 139, 4945, 10.1210/endo.139.12.6412 · DOI
  39. Chawla, 2001, Science, 294, 1866, 10.1126/science.294.5548.1866 · DOI · Paper page
  40. Hashimoto, 2005, J. Biol. Chem., 281, 295, 10.1074/jbc.M507877200 · DOI
  41. Kawai, 2004, Endocrinology, 145, 5515, 10.1210/en.2004-0382 · DOI
  42. Caturla, 1997, Mol. Cell. Endocrinol., 135, 139, 10.1016/S0303-7207(97)00196-2 · DOI
  43. Pfahl, 1993, Endocr. Rev., 14, 651
  44. Rogatsky, 2001, EMBO J., 20, 6071, 10.1093/emboj/20.21.6071 · DOI
  45. Sasaki, 1999, EMBO J., 18, 5389, 10.1093/emboj/18.19.5389 · DOI
  46. Kamei, 1996, Cell, 85, 403, 10.1016/S0092-8674(00)81118-6 · DOI · Paper page
  47. Tagami, 1997, Mol. Cell. Biol., 17, 2642, 10.1128/MCB.17.5.2642 · DOI
  48. Fruchart-Najib, 2004, Biochem. Biophys. Res. Commun., 319, 397, 10.1016/j.bbrc.2004.05.003 · DOI
  49. Merkel, 2005, J. Biol. Chem., 280, 21553, 10.1074/jbc.M411412200 · DOI
  50. Prieur, 2005, J. Biol. Chem., 280, 27533, 10.1074/jbc.M503139200 · DOI

Cited by

Sorted by citations

Metadata

Authors
Fugier, C., Tousaint, J.-J., Prieur, X., Plateroti, M., Samarut, J., & Delerive, P.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2006-04
Volume
281
Issue
17
Pages
11553-11559
ISSN
0021-9258
DOI
10.1074/jbc.m512554200
Cited by
60
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review